此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Prematurity and Respiratory Outcomes Program (PROP) (PROP)

2016年11月4日 更新者:University of Pennsylvania

Prematurity and Respiratory Outcomes Program (PROP) Core Database Protocol

In survivors of extreme prematurity to 36 weeks Post Menstrual Age (PMA), specific biologic, physiologic and clinical data obtained during the initial hospitalization will predict respiratory morbidity as defined by respiratory health care utilization and respiratory symptoms, between discharge and 1 year corrected age.

This protocol describes a collaboratively developed multicenter study of very preterm infants from birth through the time of discharge from the Neonatal Intensive Care Unit (NICU) and up to 1 year of age, corrected for the degree of prematurity.

研究概览

地位

完全的

详细说明

The primary goal of the PROP studies is to identify biomarkers (biochemical, physiological and genetic) and clinical variables that are associated with and thus potentially predictive of pulmonary status in preterm infants up to 1 year corrected age. An objective and validated measure of pulmonary outcome at 1 year does not currently exist. Some promising measures are in development but not yet ready for use in a multi-center large clinical study.

Moreover, the burden of chronic respiratory illness on the infants and their families is of utmost importance. A composite primary outcome of morbidity that is based on serial parental reports of respiratory symptoms, medications, hospitalizations and dependence on technology during the first year of life has been developed.

Data collection for the outcome assessment will be based on interviews conducted with the infant's main caregiver at 3, 6, 9 and 12 months corrected age. The time frame for data collection is based on questions "since last contact." Numerous epidemiological studies of asthma have used parental or self report of symptoms, physician-diagnosed asthma and allergies, or the use of medications (which may abrogate symptoms) as critical outcomes.

Survey items selected for the determination of the primary outcome will be focused on the following four domains, with any positive response to any element identifying morbidity:

  1. Respiratory medications: inhaled bronchodilators, inhaled steroids, systemic steroids, methylxanthines, diuretics, pulmonary vasodilators
  2. Hospitalizations for cardiopulmonary causes: any hospitalization regardless of duration
  3. Symptoms: any wheeze, cough without cold
  4. Home technology dependence: use of home oxygen, ventilator or continuous positive airway pressure (CPAP or BiPAP) of any duration since last contact

The primary outcome will be dichotomous, and defined as "No substantial post-prematurity respiratory disease" or "Post-prematurity respiratory disease." To be classified as having post-prematurity respiratory disease, infants must have a positive response in at least 1 of 4 morbidity domains during at least 2 separate parental interviews. Quarterly data collection up to 1 year corrected age will allow us to identify phenotypes based on the trajectory of post-prematurity respiratory disease and how these different trajectories predict later lung function and the diagnosis of asthma, if we continue to follow this cohort of children.

During hospitalization, all centers will obtain samples of tracheal aspirate, urine and saliva (for DNA extraction) from enrolled infants. At 36 weeks PMA, infants will have respiratory assessments dependent upon their respiratory status: i) respiratory inductive plethysmography (RIP) assesses alterations in tidal breathing resulting from reduced lung compliance and airway obstruction, ii) and a room air challenge (RAC).

研究类型

观察性的

注册 (实际的)

835

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Oakland、California、美国、94609
        • Alta Bates Summit Medical Center
      • San Francisco、California、美国、94143
        • University of California, San Francisco
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Indiana University Health/Riley Hospital for Children
    • Missouri
      • St Louis、Missouri、美国、63130
        • Washington Universitiy
    • New York
      • Buffalo、New York、美国、14260
        • University of Buffalo
      • Rochester、New York、美国、14642
        • University of Rochester
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University Medical Center
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital
      • Cincinnati、Ohio、美国、45220
        • Good Samaritan Hospital
      • Cincinnati、Ohio、美国、45219
        • Cincinnati University Hospital
    • Tennessee
      • Jackson、Tennessee、美国、38301
        • Jackson-Madison County General Hospital
      • Nashville、Tennessee、美国、37232
        • Monroe Carell Jr Children's Hospital at Vanderbilt
    • Texas
      • Houston、Texas、美国、77030
        • University of Texas, Houston

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1天 至 1周 (孩子)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Infants admitted to the Neonatal Intensive Care Unit who are < 29 weeks gestational age

描述

Inclusion Criteria:

  • Infants who are less than or equal to 7 days old
  • Gestational Age (GA) between 23 weeks and 0/7 days and 28 weeks and 6/7 days

Exclusion Criteria:

  • Infants who meet any of the following conditions will be excluded from the PROP cohort:

    1. The infant is not considered to be viable (decision made not to provide life-saving therapies)
    2. Congenital heart disease (not including PDA and hemodynamically insignificant VSD or ASD)
    3. Structural abnormalities of the upper airway, lungs or chest wall
    4. Other congenital malformations or syndromes that adversely affect life expectancy or cardio-pulmonary development
    5. Family is unlikely to be available for long-term follow-up

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Infant Pulmonary Function Testing (iPFT)
A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Respiratory morbidity
大体时间:1 year (corrected age)
The primary goal of the PROP studies (single center and multicenter protocols) is to identify biomarkers (biochemical, physiological and genetic) and clinical variables that are associated with and thus potentially predictive of pulmonary status in preterm infants up to 1 year corrected age.
1 year (corrected age)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Barbara K Schmidt, MD、University of Pennsylvania
  • 首席研究员:Jonas H Ellenberg, PhD、University of Pennsylvania
  • 首席研究员:Gloria S Pryhuber, MD、University of Rochester
  • 首席研究员:Alan H Jobe, MD, PhD、Cincinnati Childrens Hospital
  • 首席研究员:Aaron Hamvas, MD、Washington University School of Medicine / St. Louis Children's Hospital
  • 首席研究员:Judy Aschner, MD、Vanderbilt University School of Medicine
  • 首席研究员:Roberta L Keller, MD、University of California San Francisco/Benioff Children's Hospital
  • 首席研究员:Judith Voynow, MD、Duke University
  • 首席研究员:Stephanie D Davis, MD、Indiana University/Riley Hospital for Children

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年8月1日

初级完成 (实际的)

2015年4月1日

研究完成 (实际的)

2016年3月1日

研究注册日期

首次提交

2011年9月14日

首先提交符合 QC 标准的

2011年9月14日

首次发布 (估计)

2011年9月16日

研究记录更新

最后更新发布 (估计)

2016年11月6日

上次提交的符合 QC 标准的更新

2016年11月4日

最后验证

2016年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 813839
  • U01HL101794-02 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅